The Prognostic Impact of Cyclin D1 Expression in Patients with Multiple Myeloma, an Egyptian Study - Abstract
Background: Multiple myeloma is a multifocal hematological disorder, which shows a proliferation of malignant plasma cells in the bone marrow, it represents approximately 1% of all malignancy, causing about 20% of deaths from hematological malignancies. Cyclin D1 is considered an important factor in the cell cycle control; dysregulation of cyclin D1 has an oncogenic role in multiple myeloma patients and can affect their prognosis.
Aim of the study: To determine the prognostic effect of cyclin D1 and correlate its expression with selected clinic-pathological features Methods: This study was conducted on fifty patients diagnosed as multiple myeloma at National Cancer Institute, Cairo University to study the expression pattern of cyclin D1 by immunohistochemistry on their bone marrow biopsy specimens, patients were followed up for one year. Results: Cyclin D1 positive expression was found in 19/50 (38%) of the patients and it was positively correlated with bone marrow fibrosis, initial serum total protein level and serum B2 microglobulin. Also, correlation of the treatment response and the outcome of the patients with cyclin D1 expression were found significant. Conclusion: Cyclin D1 has a significant poor prognosis in multiple myeloma patients